Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00811733 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
A Phase 2 study of Waldenstrom Macroglobulinaemia, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 7
- Study locations
NCT00811733 is a Phase 2 study of Waldenstrom Macroglobulinaemia that has completed, run by GlaxoSmithKline. The registered enrollment target is 37 participants. The trial reports 7 study locations across 5 states.
The verdict
NCT00811733, a Phase 2 study of Waldenstrom Macroglobulinaemia, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 7
- Study locations
Study Summary
Given the tolerability and efficacy of ofatumumab in follicular lymphoma and Chronic Lymphocytic Leukemia, and the need to improve therapy for patients with WM utilizing a non-myelosuppressive agent this phase II trial of ofatumumab is being initiated in patients with Waldenstrom's Macroglobulinemia (WM).
Conditions Studied
Interventions
- BIOLOGICAL Ofatumumab
Study Locations (7)
California
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Stanford
New York
- GSK Investigational Site - Buffalo
- GSK Investigational Site - New York
Minnesota
- GSK Investigational Site - Rochester
Ohio
- GSK Investigational Site - Columbus
Texas
- GSK Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2009-03-01 |
| Est. Completion | 2014-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00811733
The ClinicalTrials.gov registry entry for NCT00811733 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Waldenstrom Macroglobulinaemia appearing as the primary indexed condition, and to 1 intervention - of which Ofatumumab is the first listed.
NCT00811733 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, New York, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00811733 about?
NCT00811733 is a clinical study titled "A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia". Given the tolerability and efficacy of ofatumumab in follicular lymphoma and Chronic Lymphocytic Leukemia, and the need to improve therapy for patients with WM utilizing a non-myelosuppressive agent this phase II trial of ofatumumab is being initiated in patients with Waldenstrom's Macroglobulinemia...
What is the current status of trial NCT00811733?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2009-03-01. Estimated completion is 2014-02-01.
What conditions does trial NCT00811733 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinaemia.
What interventions are being tested in trial NCT00811733?
The interventions under investigation include: Ofatumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00811733?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00811733 being conducted?
This trial has 7 study locations across California, Minnesota, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.